{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:05:59Z","timestamp":1787537159707,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070220, 82270209"],"award-info":[{"award-number":["82070220, 82270209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the characteristics of patients with multiple myeloma (MM) who have achieved long-term survival of over 10 years in the context where novel agents and autologous stem cell transplantation (ASCT) serve as the primary therapeutic modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 168 MM patients diagnosed and treated in our institution from January 2004 to January 2014. 44 patients with a survival period exceeding 10 years were categorized into the long-term survival group, while 124 patients with a survival period of less than 10 years were categorized into the non-long-term survival group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Being younger than 57 years old (OR 3.634, 95%CI 1.302-10.143), having a neutrophil count of at least 3.66 * 10<jats:sup>9<\/jats:sup>\/L (OR 3.122, 95% CI 1.093-8.918), absence of high-risk genetic abnormalities (OR 7.146, 95%CI  1.066-47.904), and receiving frontline ASCT (OR 4.225, 95%CI 1.000-17.841) were positively associated with a survival period exceeding 10 years in patients with MM. Achieving sustained minimal residual disease (MRD) negativity for at least 24 months is associated with long-term survival regardless of the presence of high-risk cytogenetic abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Being younger, having a neutrophil count above 3.66 * 10<jats:sup>9<\/jats:sup>\/L, the absence of high-risk cytogenetic abnormalities, and receiving frontline ASCT are independent protective factors for transplant-eligible MM patients to survive more than 10 years. Achieving maintained MRD negativity status for over 24 months might be associated with long-term survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1490630","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:26:57Z","timestamp":1732170417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The characteristics of patients with multiple myeloma surviving over 10 years"],"prefix":"10.3389","volume":"14","author":[{"given":"Beihui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe fran\u00e7ais du my\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06745.x","article-title":"Ten-year survival and prognostic factors in multiple myeloma. Japan myeloma study group","volume":"87","author":"Tsuchiya","year":"1994","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plusprednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: A report from the canadian myeloma research group database","volume":"13","author":"Cote","year":"2023","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17350","article-title":"Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: A multi-institutional report from the canadian myeloma research group database","volume":"193","author":"Jimenez-Zepeda","year":"2021","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long Pfs of More Than 7 years Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents: A Single-Center Experience over 20-Year Period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Candor): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (Cassiopeia): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet (London England)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (Boston): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet (London England)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"New Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (Optimismm): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20220309-00165","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)","volume":"61","author":"Cai","year":"2022","journal-title":"Zhonghua nei ke za zhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an imwg research project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1517\/17425247.2015.993313","article-title":"Albumin and its application in drug delivery","volume":"12","author":"Sleep","year":"2015","journal-title":"Expert Opin Drug Delivery"},{"key":"B23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2023.07.003","article-title":"Albumin administration in internal medicine: A journey between effectiveness and futility","volume":"117","author":"Pompili","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.08.030","article-title":"Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: review and meta-analysis","volume":"486","author":"Wang","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.39.5.7781","article-title":"Prognostic nutritional index (Pni) and controlling nutritional status (Conut) score for predicting outcomes of breast cancer: A systematic review and meta-analysis","volume":"39","author":"Peng","year":"2023","journal-title":"Pak J Med Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2018.1559930","article-title":"Prognostic role of the prognostic nutritional index in pancreatic cancer: A meta-analysis","volume":"71","author":"Li","year":"2019","journal-title":"Nutr Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12957-021-02253-y","article-title":"Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis","volume":"19","author":"Liao","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2018","article-title":"The neutrophil's role during health and disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S108419","article-title":"The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis","volume":"9","author":"Wei","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0311-2","article-title":"Blood neutrophil\u2013lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy folfox 4","volume":"31","author":"el Aziz","year":"2014","journal-title":"Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22107","article-title":"Pretreatment neutrophil\/lymphocyte ratio but not platelet\/lymphocyte ratio has a prognostic impact in multiple myeloma","volume":"31","author":"Li","year":"2017","journal-title":"J Clin Lab Anal"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (Emn02\/ho95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (Asct) followed by lenalidomide (R) or carfilzomib-lenalidomide (Kr) maintenance: efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-krd) in front-line treatment of high-risk multiple myeloma: interim analysis of the gmmg-concept trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.05.001","article-title":"Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021)","volume":"42","author":"Li","year":"2021","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal flow cytometry identified \"Minimal residual disease\" (Mrd) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Bai","year":"2017","journal-title":"Br J Haematology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep mrd profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (Gmmg-hd7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: A systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 forte trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160004%JBlood","article-title":"Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: A european myeloma network study (Emn19)","volume":"140","author":"Beksac","year":"2022","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846772.63169.c5","article-title":"P976: bendamustine-pomalidomide-dexamethasone (Bpd) for relapsed and\/or refractor multiple myeloma with extramedullary disease","volume":"6","author":"Yuping","year":"2022","journal-title":"Hemasphere"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic Malignancies working party of the ebmt","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from balkan myeloma study group and barcelona university: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of vgpr to induction therapy is an important prognostic factor for longer pfs in the ifm 2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1490630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:27:04Z","timestamp":1732170424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1490630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":57,"alternative-id":["10.3389\/fonc.2024.1490630"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1490630","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"article-number":"1490630"}}